EF5 Compound, 150 mg

A number of imaging markers which target hypoxia exist and are widely used in research. EF5 (2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide) is a compound developed at the University of Pennsylvania by Dr. Cameron Koch and Dr. Sydney Evans. Upon injection into animal tissues, EF5 selectively binds to hypoxic cells and forms adducts. A mouse monoclonal antibody, clone ELK3-51 which is directly conjugated to either Cyanine 3 or Alexa Fluor^™ 488 is then used to selectively bind the EF5 adducts.

Advantages of the EF5 Hypoxia Detection:
• EF5 exists in only one form:
Pimidozole, an alternative hypoxia marker, exists in two forms; one of which is charged and very hydrophilic, the other lipophilic. Pimidozole thus has a very complex biodistribution. In contrast, EF5 is lipophilic and uncharged and this allows very rapid and even tissue distribution.

Reference:
Koch CJ (2002) Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods in Enzymology 352: 3-31.

EF5 is a 2-nitroimidazole-based hypoxia marker that selectively binds hypoxic cells.

EF5 Compound, CAS 152721-37-4: 1 vial containing 150 mg. Store at -20°C.

Store at -20°C.

ALEXA FLUOR is a trademark of Life Technologies

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.